JP2018093875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018093875A5 JP2018093875A5 JP2017253096A JP2017253096A JP2018093875A5 JP 2018093875 A5 JP2018093875 A5 JP 2018093875A5 JP 2017253096 A JP2017253096 A JP 2017253096A JP 2017253096 A JP2017253096 A JP 2017253096A JP 2018093875 A5 JP2018093875 A5 JP 2018093875A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- chain variable
- variable region
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004927 fusion Effects 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 claims 4
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- 230000024203 complement activation Effects 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 102000054960 human MASP2 Human genes 0.000 claims 2
- 238000000099 in vitro assay Methods 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000012385 systemic delivery Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361962289P | 2013-03-15 | 2013-03-15 | |
| US61/962,289 | 2013-03-15 | ||
| US201361823964P | 2013-05-16 | 2013-05-16 | |
| US61/823,964 | 2013-05-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502958A Division JP2016514456A (ja) | 2013-03-15 | 2014-03-14 | 生物活性ペプチド担持抗体を生成する方法およびそれを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018093875A JP2018093875A (ja) | 2018-06-21 |
| JP2018093875A5 true JP2018093875A5 (Direct) | 2018-08-16 |
| JP6615854B2 JP6615854B2 (ja) | 2019-12-04 |
Family
ID=51538337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502958A Withdrawn JP2016514456A (ja) | 2013-03-15 | 2014-03-14 | 生物活性ペプチド担持抗体を生成する方法およびそれを含む組成物 |
| JP2017253096A Active JP6615854B2 (ja) | 2013-03-15 | 2017-12-28 | 生物活性ペプチド担持抗体を生成する方法およびそれを含む組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502958A Withdrawn JP2016514456A (ja) | 2013-03-15 | 2014-03-14 | 生物活性ペプチド担持抗体を生成する方法およびそれを含む組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20150017162A1 (Direct) |
| EP (1) | EP2968546B1 (Direct) |
| JP (2) | JP2016514456A (Direct) |
| AU (3) | AU2014229020B2 (Direct) |
| CA (1) | CA2906096C (Direct) |
| ES (1) | ES2964340T3 (Direct) |
| NZ (2) | NZ729747A (Direct) |
| WO (1) | WO2014144542A2 (Direct) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140363433A1 (en) * | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| WO2014144542A2 (en) * | 2013-03-15 | 2014-09-18 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| CN107208315A (zh) * | 2014-12-01 | 2017-09-26 | 斯克利普斯研究院 | 涉及嵌入异源蛋白质支架中的功能性多肽的方法和组合物 |
| KR102528260B1 (ko) * | 2016-01-05 | 2023-05-04 | 유니버시티 오브 레스터 | 필요로 하는 대상체에서 섬유증의 억제 방법 |
| JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| WO2018186322A1 (en) * | 2017-04-03 | 2018-10-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-masp-1 antibodies and methods of use |
| EP3606952A1 (en) | 2017-04-07 | 2020-02-12 | Miltenyi Biotec GmbH | POLYPEPTIDES WITH MUTANT HUMAN IgG4 |
| KR20210008027A (ko) * | 2018-05-10 | 2021-01-20 | 미라바이오로직스 가부시키가이샤 | 항체의 항원 결합 영역을 포함하고, 생리 활성 펩티드를 융합하는 인공 단백질 |
| WO2020225095A1 (en) | 2019-05-07 | 2020-11-12 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| TWI867422B (zh) | 2020-03-06 | 2024-12-21 | 美商奥默羅斯公司 | 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法 |
| EP4240750A1 (en) | 2020-11-04 | 2023-09-13 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| EP4011904A1 (en) | 2020-12-14 | 2022-06-15 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| TW202305010A (zh) * | 2021-04-25 | 2023-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
| US20050033033A1 (en) * | 1998-05-04 | 2005-02-10 | Heinz Kohler | Trans-membrane-antibody induced inhibition of apoptosis |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| KR100490669B1 (ko) * | 2001-08-30 | 2005-05-19 | (주)아비코아생명공학연구소 | 조류 콕시듐증을 유발하는 에이메리아 종의 포자소체 표면항원에 대한 ｓｃＦｖ 재조합 항체 |
| CA2490409A1 (en) * | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
| KR101101261B1 (ko) | 2002-07-19 | 2012-01-04 | 인스티튜트 오브 머티어리얼스 리서치 & 엔지니어링 | 생체분해성 삼블럭 공중합체, 이의 합성 방법, 및이로부터 제조된 하이드로겔 및 생체물질 |
| CA2518119A1 (en) * | 2003-03-05 | 2004-09-16 | Innexus Biotechnology Inc. | Trans-membrane-antibody induced inhibition of apoptosis |
| ES2541134T3 (es) * | 2003-05-12 | 2015-07-16 | Helion Biotech Aps | Anticuerpos de MASP-2 |
| US20130266559A1 (en) | 2004-06-10 | 2013-10-10 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP1844073A1 (en) | 2005-01-31 | 2007-10-17 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| WO2007048022A2 (en) * | 2005-10-21 | 2007-04-26 | Alexion Pharmaceuticals, Inc. | Antibody-polypeptide fusion proteins and methods for producing and using same |
| PE20070684A1 (es) * | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
| KR20080090406A (ko) | 2005-11-28 | 2008-10-08 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| ES2628973T3 (es) | 2007-05-31 | 2017-08-04 | University Of Washington | Mutagénesis inducible de genes diana |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| WO2010136483A2 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| EP2488203B1 (en) | 2009-10-16 | 2016-12-07 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| WO2012000777A1 (en) | 2010-07-01 | 2012-01-05 | Thomson Licensing | Method for calibrating a band rejection filter of a terminal and multistandard terminal with calibrated band rejection filter |
| HUP1000366A2 (en) * | 2010-07-13 | 2012-03-28 | Mta Enzimologiai Intezet | Novel proteins, their production process and use tereof |
| CN110075294A (zh) * | 2011-04-08 | 2019-08-02 | 莱斯特大学 | 用于治疗与masp-2依赖性补体活化相关的状况的方法 |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP3725811A3 (en) | 2011-05-04 | 2021-01-27 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement activation |
| CN103826659A (zh) * | 2011-06-20 | 2014-05-28 | 圣路易斯大学 | 用于治疗的靶向神经肌肉接头 |
| ES2894944T3 (es) * | 2012-04-06 | 2022-02-16 | Omeros Corp | Composiciones y métodos para inhibir la MASP-1 y/o la MASP-2 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica |
| KR102339315B1 (ko) | 2012-06-18 | 2021-12-15 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
| WO2014144542A2 (en) * | 2013-03-15 | 2014-09-18 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2014
- 2014-03-14 WO PCT/US2014/028999 patent/WO2014144542A2/en not_active Ceased
- 2014-03-14 US US14/213,630 patent/US20150017162A1/en not_active Abandoned
- 2014-03-14 JP JP2016502958A patent/JP2016514456A/ja not_active Withdrawn
- 2014-03-14 AU AU2014229020A patent/AU2014229020B2/en active Active
- 2014-03-14 EP EP14764165.8A patent/EP2968546B1/en active Active
- 2014-03-14 NZ NZ729747A patent/NZ729747A/en unknown
- 2014-03-14 ES ES14764165T patent/ES2964340T3/es active Active
- 2014-03-14 CA CA2906096A patent/CA2906096C/en active Active
- 2014-03-14 NZ NZ629682A patent/NZ629682A/en unknown
-
2017
- 2017-12-15 AU AU2017276336A patent/AU2017276336A1/en not_active Abandoned
- 2017-12-28 JP JP2017253096A patent/JP6615854B2/ja active Active
-
2019
- 2019-09-05 AU AU2019226184A patent/AU2019226184B2/en active Active
-
2020
- 2020-08-04 US US16/984,287 patent/US20210079117A1/en not_active Abandoned
-
2024
- 2024-09-27 US US18/900,179 patent/US20250122309A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018093875A5 (Direct) | ||
| JP7143452B2 (ja) | ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用 | |
| JP2021503455A5 (Direct) | ||
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| IL266756A (en) | Human monoclonal antibodies that bind to MASP 2 and suppress MASP-dependent complement activation, methods for their production and uses | |
| JP2018108081A5 (Direct) | ||
| JP2019533719A5 (Direct) | ||
| JP2017500018A5 (Direct) | ||
| JP2017523786A5 (Direct) | ||
| JP2012525829A5 (Direct) | ||
| HRP20170374T1 (hr) | Biološki proizvodi | |
| TW201837174A (zh) | 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子 | |
| JP2019516394A (ja) | 新規抗ｐｄ−ｌ１抗体 | |
| JP2024056687A5 (Direct) | ||
| JP2021508707A5 (Direct) | ||
| JP2017536341A5 (Direct) | ||
| JP2017530722A5 (Direct) | ||
| NZ585559A (en) | Humanized antibodies against tl1a | |
| AU2021221287B2 (en) | Engineered anti-IL-2 antibodies | |
| HRP20220637T1 (hr) | Protutijela anti-komplementa c1s i njihova upotreba | |
| KR20220113353A (ko) | Ceacam5 및 cd3에 대한 이중특이적 항체 | |
| RU2016145277A (ru) | Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака | |
| JP2011506483A5 (Direct) | ||
| JP2020524661A5 (Direct) | ||
| JP2016538318A5 (Direct) |